Physitrack PLC

Physitrack PLC operates globally as a digital healthcare innovator. The company delivers a proprietary cloud-based Software-as-a-Service (SaaS) platform, utilized by a diverse range of healthcare providers, from individual practitioners to large organizations, to completely digitalize the patient journey—from their initial contact through ongoing interactions and tracking of progress. Additionally, Physitrack offers virtual care solutions that address three key areas for patients and insurance plan members: preventive and wellness support, care for acute and chronic conditions, and surgical recovery. These virtual care services are supplied to healthcare enterprises such as private and public hospitals, clinics, and other health businesses. Founded in 2012, the company was formerly known as Physitrack Limited before rebranding to Physitrack PLC in May 2021 and is based in London, United Kingdom.

Physitrack PLC trades as PTRK.ST on STO. The company is classified in Healthcare / Medical - Healthcare Information Services and reports in SEK.

The current profile places the business in Medical - Healthcare Information Services. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Physitrack PLC can be compared against peers such as AlzeCure Pharma AB (publ), Bio-Works Technologies AB (publ), Boule Diagnostics AB (publ), Clinical Laserthermia Systems AB (publ), IRLAB Therapeutics AB (publ), Isofol Medical AB (publ).

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $132.36M, beta of 0.57, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

PTRK.ST currently shows total debt of N/A and beta of 0.57. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.physitrack.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.